|Assessment Status||Rapid Review Complete|
|Indication||As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.|
|Rapid review commissioned||11/05/2021|
|Rapid review completed||15/06/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that olaparib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.